347 related articles for article (PubMed ID: 25511923)
41. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
[TBL] [Abstract][Full Text] [Related]
43. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
44. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
45. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
[TBL] [Abstract][Full Text] [Related]
46. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
47. Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting.
Singh N; Goyal A
J Clin Oncol; 2013 Mar; 31(9):1250-1. PubMed ID: 23382469
[No Abstract] [Full Text] [Related]
48. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.
González García J; Gutiérrez Nicolás F; Nazco Casariego GJ; Valcárcel Nazco C; Batista López JN; Oramas Rodríguez J
Farm Hosp; 2017 Jan; 41(n01):3-13. PubMed ID: 28045649
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.
Chouaïd C; Crequit P; Borget I; Vergnenegre A
Clinicoecon Outcomes Res; 2015; 7():9-15. PubMed ID: 25548525
[TBL] [Abstract][Full Text] [Related]
51. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
Bischoff HG; Heigener DF; Walzer S; Nuijten M
Lung Cancer; 2010 Aug; 69 Suppl 1():S18-23. PubMed ID: 20727458
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
Zheng H; Xie L; Zhan M; Wen F; Xu T; Li Q
Clin Transl Oncol; 2018 Mar; 20(3):286-293. PubMed ID: 28785913
[TBL] [Abstract][Full Text] [Related]
53. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
[TBL] [Abstract][Full Text] [Related]
54. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C; Le Caer H; Corre R; Crequit J; Locher C; Falchero L; Dujon C; Berard H; Monnet I; Vergnenegre A
Clin Lung Cancer; 2013 Mar; 14(2):103-7. PubMed ID: 22682669
[TBL] [Abstract][Full Text] [Related]
55. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.
Tsukiyama I; Ejiri M; Yamamoto Y; Nakao H; Yoneda M; Matsuura K; Arakawa I; Saito H; Inoue T
J Gastrointest Cancer; 2017 Dec; 48(4):326-332. PubMed ID: 27785685
[TBL] [Abstract][Full Text] [Related]
56. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(1):75-92. PubMed ID: 20014878
[TBL] [Abstract][Full Text] [Related]
57. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
[TBL] [Abstract][Full Text] [Related]
59. Erlotinib for the treatment of relapsed non-small cell lung cancer.
McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
Giuliani G; Grossi F; de Marinis F; Walzer S
Lung Cancer; 2010 Aug; 69 Suppl 1():S11-7. PubMed ID: 20727457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
